Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis.

Chou RC, Kane M, Ghimire S, Gautam S, Gui J.

CNS Drugs. 2016 Nov;30(11):1111-1120.

2.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

3.

Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

Singh JA, Hossain A, Mudano AS, Tanjong Ghogomu E, Suarez-Almazor ME, Buchbinder R, Maxwell LJ, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2017 May 8;5:CD012657. doi: 10.1002/14651858.CD012657. Review.

PMID:
28481462
4.

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

PMID:
19224750
5.

Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.

Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR.

Ann Rheum Dis. 2015 Jun;74(6):1065-71. doi: 10.1136/annrheumdis-2013-204011. Epub 2014 Mar 7.

6.
7.

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.

van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.

Ann Rheum Dis. 2013 Jun;72(6):895-900. doi: 10.1136/annrheumdis-2012-201338. Epub 2012 Aug 11.

PMID:
22887849
8.

Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.

Segan J, Staples MP, March L, Lassere M, Chakravarty EF, Buchbinder R.

Intern Med J. 2015 Mar;45(3):310-8. doi: 10.1111/imj.12679.

PMID:
25565419
9.

Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.

Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM.

Rheumatology (Oxford). 2007 Nov;46(11):1688-93. Epub 2007 Oct 15.

10.

"Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study".

Wasson NJ, Varley CD, Schwab P, Fu R, Winthrop KL.

BMC Infect Dis. 2013 Nov 11;13:533. doi: 10.1186/1471-2334-13-533.

11.

Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.

Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, Mikuls TR, Delzell E, Saag KG, Safford MM, DuVall S, Alexander K, Napalkov P, Winthrop KL, Burton MJ, Kamauu A, Baddley JW.

Arthritis Care Res (Hoboken). 2014 Jul;66(7):990-7. doi: 10.1002/acr.22281.

12.

Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.

Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.

J Manag Care Spec Pharm. 2014 Jul;20(7):657-67.

13.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
14.

Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.

Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1480-9. doi: 10.1002/acr.21805.

15.
16.

Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.

Johnston SS, Turpcu A, Shi N, Fowler R, Chu BC, Alexander K.

Semin Arthritis Rheum. 2013 Aug;43(1):39-47. doi: 10.1016/j.semarthrit.2012.12.024. Epub 2013 Feb 27.

PMID:
23453683
17.

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.

Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2016 May 13;(5):CD012183. doi: 10.1002/14651858.CD012183. Review.

PMID:
27175934
18.

The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.

Wu CY, Chen DY, Shen JL, Ho HJ, Chen CC, Kuo KN, Liu HN, Chang YT, Chen YJ.

Arthritis Res Ther. 2014 Sep 30;16(5):449. doi: 10.1186/s13075-014-0449-5. Erratum in: Arthritis Res Ther. 2016;18(1):110.

19.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

20.

Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.

Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Askling J; Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.

Arthritis Rheum. 2012 Jan;64(1):42-52. doi: 10.1002/art.30654.

Supplemental Content

Support Center